A. Ramesh, A. Chatterjee, R.M. Subramaniam, Neuroendocrine neoplasms: epidemiology, diagnosis, and management. PET Clin. 18, 161–168 (2023)

Article  PubMed  Google Scholar 

R.M. Ruggeri, E. Benevento, F. De Cicco et al. Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies. J. Endocrinol. Invest 46, 213–234 (2023)

Article  CAS  PubMed  Google Scholar 

S. Das, A. Dasari, Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr. Oncol. Rep. 23, 43 (2021)

Article  PubMed  PubMed Central  Google Scholar 

A. Faggiano, S. Di Maio, C. Mocerino et al. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine 66, 417–424 (2019)

Article  CAS  PubMed  Google Scholar 

A. La Salvia, D. Giuffrida, R. Modica, Editorial: neuroendocrine tumors: the road to precision medicine. Front Endocrinol. (Lausanne) 14, 1253319 (2023)

Article  PubMed  Google Scholar 

R. Modica, A. Liccardi, R. Minotta et al. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev. Endocrinol. Metab. 17, 389–403 (2022)

Article  CAS  PubMed  Google Scholar 

G. Fanciulli, R. Modica, A. La Salvia et al. Proteasome inhibitors in medullary thyroid carcinoma: time to restart with clinical trials? Front Endocrinol. (Lausanne) 14, 1145926 (2023)

Article  PubMed  Google Scholar 

G. Fanciulli, R. Modica, A. La Salvia et al. Immunotherapy of neuroendocrine neoplasms: Any role for the chimeric antigen receptor T cells? Cancers (Basel) 14, 3991 (2022)

Article  CAS  PubMed  Google Scholar 

V. Melone, A. Salvati, D. Palumbo et al. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis. J. Transl. Med. 20, 306 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

J. Gu, N. Zhu, H.-F. Li et al. Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. Cell Oncol. (Dordr.) 45, 709–728 (2022)

Article  CAS  PubMed  Google Scholar 

B. Huang, B.-L. Song, C. Xu, Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat. Metab. 2, 132–141 (2020)

Article  PubMed  Google Scholar 

R. Modica, E. Benevento, A. Colao, Endocrine-disrupting chemicals (EDCs) and cancer: new perspectives on an old relationship. J. Endocrinol. Invest 46, 667–677 (2023)

Article  CAS  PubMed  Google Scholar 

H. Xu, S. Zhou, Q. Tang et al. Cholesterol metabolism: New functions and therapeutic approaches in cancer. Biochim Biophys. Acta Rev. Cancer 1874, 188394 (2020)

Article  CAS  PubMed  Google Scholar 

T. Murai, Cholesterol lowering: role in cancer prevention and treatment. Biol. Chem. 396, 1–11 (2015)

Article  ADS  CAS  PubMed  Google Scholar 

B. Smith, H. Land, Anticancer activity of the cholesterol exporter ABCA1 gene. Cell Rep. 2, 580–590 (2012)

Article  CAS  PubMed  PubMed Central  Google Scholar 

R. Muniyappa, M.A. Warren, X. Zhao et al. Reduced insulin sensitivity in adults with pseudohypoparathyroidism type 1a. J. Clin. Endocrinol. Metab. 98, E1796–E1801 (2013)

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Vasseur, F. Guillaumond, Lipids in cancer: a global view of the contribution of lipid pathways to metastatic formation and treatment resistance. Oncogenesis 11, 46 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

T. Feola, G. Puliani, F. Sesti et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J. Endocrinol. Invest 45, 849–857 (2022)

Article  CAS  PubMed  Google Scholar 

S.L. Gonias, N. Karimi-Mostowfi, S.S. Murray et al. Expression of LDL receptor-related proteins (LRPs) in common solid malignancies correlates with patient survival. PLoS One 12, e0186649 (2017)

Article  PubMed  PubMed Central  Google Scholar 

Z. Roslan, M. Muhamad, L. Selvaratnam et al. The roles of low-density lipoprotein receptor-related proteins 5, 6, and 8 in cancer: A review. J. Oncol. 2019, 4536302 (2019)

Article  PubMed  PubMed Central  Google Scholar 

C. Wang, P. Li, J. Xuan et al. Cholesterol enhances colorectal cancer progression via ROS elevation and MAPK signaling pathway activation. Cell Physiol. Biochem 42, 729–742 (2017)

Article  CAS  PubMed  Google Scholar 

K.K. Patel, K. Kashfi, Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs. Biochem Pharm. 196, 114654 (2022)

Article  CAS  PubMed  Google Scholar 

G. Revilla, L. Cedó, M. Tondo et al. LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies. Semin Cancer Biol. 73, 134–157 (2021)

Article  CAS  PubMed  Google Scholar 

R. Modica, A. La Salvia, A. Liccardi et al. Lipid metabolism and homeostasis in patients with neuroendocrine neoplasms: from risk factor to potential therapeutic target. Metabolites 12, 1057 (2022)

Article  CAS  PubMed  PubMed Central  Google Scholar 

A. Natalicchio, A. Faggiano, M.C. Zatelli et al. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit. Rev. Oncol. Hematol. 169, 103572 (2022)

Article  PubMed  Google Scholar 

L. Barrea, G. Muscogiuri, R. Modica et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol. (Lausanne) 12, 649496 (2021)

Article  PubMed  Google Scholar 

A. Faggiano, F. Lo Calzo, G. Pizza et al. The safety of available treatments options for neuroendocrine tumors. Expert Opin. Drug Saf. 16, 1149–1161 (2017)

Article  CAS  PubMed  Google Scholar 

A. Khalifa, A. Guijarro, S. Ravera et al. Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity. Nat. Commun. 14, 6951 (2023)

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

A. Colao, F. de Nigris, R. Modica et al. Clinical epigenetics of neuroendocrine tumors: The road ahead. Front Endocrinol. (Lausanne) 11, 604341 (2020)

Article  PubMed  Google Scholar 

S. Das, S.J. Freedland, Statins and cancer prevention-association does not mean causation. Cancer Prev. Res (Philos.) 16, 1–3 (2023)

Article  Google Scholar 

A.D. Herrera-Martínez, S. Pedraza-Arevalo, F. L-López et al. Type 2 diabetes in neuroendocrine tumors: are biguanides and statins part of the solution? J. Clin. Endocrinol. Metab. 104, 57–73 (2019)

Article  PubMed  Google Scholar 

K. Mahboobnia, M. Pirro, E. Marini et al. PCSK9 and cancer: Rethinking the link. Biomed. Pharmacother. 140, 111758 (2021)

Article  CAS  PubMed  Google Scholar 

V. Katsi, I. Papakonstantinou, K. Tsioufis, Atherosclerosis, diabetes mellitus, and cancer: common epidemiology, shared mechanisms, and future management. Int J. Mol. Sci. 24, 11786 (2023

Article  CAS  PubMed  PubMed Central  Google Scholar 

P. Gazzerro, M.C. Proto, G. Gangemi et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharm. Rev. 64, 102–146 (2012)

Article  CAS  PubMed  Google Scholar 

R. Liu, W. Wang, L. Ye et al. p21-activated kinase 3 is overexpressed in thymic neuroendocrine tumors (carcinoids) with ectopic ACTH syndrome and participates in cell migration. Endocrine 38, 38–47 (2010)

Article  PubMed  Google Scholar 

B. Zarebczan, H. Chen, Signaling mechanisms in neuroendocrine tumors as targets for therapy. Endocrinol. Metab. Clin. North Am. 39, 801–810 (2010)

Article  CAS  PubMed  PubMed Central  Google Scholar 

Z. Kraiem, G. Maor, M. Silbermann, Dexamethasone and 8-bromo-cyclic AMP depress the incorporation of [3H]thymidine into mouse condylar cartilage by different pathways. J. Endocrinol. 109, 209–213 (1986

Article  CAS  PubMed